Compare Enovix Corporation (ENVX) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Tempus AI — how do they compare? Enovix Corporation trades at $2.46 (market cap $549.72M), while Tempus AI trades at $70.93 (market cap $12.58B). The key difference: Tempus AI is far larger — about 22.9× Enovix Corporation's market cap, and Tempus AI is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Tempus AI for 23 Days on average.
| ENVX | TEM | |
|---|---|---|
Market Cap | $549.72M | $12.58B |
Volume | 6,635,687 | 7,444,569 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $13.19 | $99.28 |
52-Week Low | $2.50 | $41.55 |
Typical Hold Time | 11 Days | 23 Days |
Enterprise Value | $611.42M | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.46, down 3.53% on the day, with technical indicators signaling a bearish trend. The company reported a net loss of $156.74 million in 2025, with revenue of $31.82 million, and continues to burn cash, though it has beaten EPS estimates in recent quarters. Recent news includes CEO transition and expansion of battery manufacturing capacity.
Despite consistent EPS beats, ENVX faces significant financial challenges with negative margins and cash burn. Analyst consensus is bullish with a $10.75 price target, but high execution risk and leadership changes pose threats to near-term stability and long-term growth prospects.
Tempus AI (TEM) trades at $69.28, down 1.44% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth (2026: $1.4B) but remains unprofitable with negative margins. Recent FDA clearance for ECG-MR AI product and ESMO Congress presentations highlight innovation momentum. Analyst consensus is strongly bullish with 64% buy ratings and $72.60 price target.
TEM offers growth potential in AI-driven healthcare diagnostics but carries significant execution risk due to persistent losses. The stock's high P/S ratio (8.61) reflects growth expectations, yet negative ROE (-67.44%) and insider selling warrant caution. Upside depends on profitability improvements and commercial adoption of new AI products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
